

### Technology


**Phylogica** is a biopharmaceutical company developing drug therapies from a new class of peptides called **Phylomers®**, which are designed to specifically block disease protein interactions. Phylogica selects the most potent and selective **Phylomer/s®** from its collection to block disease-causing targets provided by its partners to help them create new therapies.

**Phylomers®** are fragments of naturally occurring proteins with the ability to bind tightly to target proteins and inactivate them [Watt PM (2006) Nature Biotechnology 24 (2):177-83]. As the most structurally diverse source of peptides available, **Phylomers®**

can be selected for potent activity against multiple classes of target proteins, both inside or outside cells. Phylogica's **Phylomer®** Libraries consist of collections of billions of **Phylomers®** and are available in a range of formats for screening against intracellular targets (via yeast two hybrid) or extracellular targets (via phage display), and can also be used for the identification and validation of potential new targets in phenotypic screens. Phylogica has already applied **Phylomer®** technology internally to discover and develop novel therapeutic leads directed at proteins and their interactions, focusing in the area of inflammatory and infectious diseases.

### PARTNERING OPPORTUNITIES

Phylogica is seeking partnering opportunities with companies which have disease protein targets. Phylogica offers to screen and select **Phylomers®** that interact with a protein target to be used as therapeutics. **Phylomer®** blockers can also be used as protein silencers to validate potential disease targets.



### Competitive Advantages

Phylogica uses a proprietary technology called the **Blocker Trap** to select the best **Phylomers®** from its collection to block the disease-causing proteins, to validate targets and create new therapies.

**Phylomers®** provide a compact replacement for antibodies with several major advantages including:

- No antibody royalty stack with simpler path to market
- Primary hits in pM-nM range before affinity maturation
- Higher activity per mass (15-60 fold more than antibodies)
- Manufacturing advantage as **Phylomers®** are small enough to be synthesized (cost and time advantage)
- **Phylomers®** are small and therefore amenable to delivery with emerging technologies including the buccal, intranasal and inhaled routes of administration
- Greater structural diversity provides multiple blocking shapes to hit more target classes
- Less chance of unintended interactions with the immune system due to small size (fewer T-cell epitopes) of **Phylomers**
- Potential to minimise anaphylactic side-effects associated with conventional protein therapeutics, due to **Phylomers'** small size (likely monovalency to prevent crosslinking)

	Antibodies	Single Chain Antibodies	Phylomers®
Clear IP Status	-	+	+++
Activity per Mass	+	++	+++
Time to Manufacture	-	-	+
Cost of Goods	-	-	+
Ease of Delivery	-	+	+++
Structural Diversity	+	+	+++
Hit Rate	+	+	++
Specificity	+++	+++	+++